Histopathology predictors of medically refractory ulcerative colitis

Diseases of the Colon and Rectum

Volumn 53, Issue 9, 2010, Pages 1280-1286

  Melson, Joshua E ^a   Giusto, Deborah ^a   Kwasny, Mary ^a   Eichenseer, Peter ^a   Jakate, Shriram ^a   Keshavarzian, Ali ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colectomy; Colitis; Histopathology; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; STEROID;

ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON RESECTION; COLON ULCER; CRYPTITIS; ENDOSCOPY; ENTEROPATHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH FOLLICLE; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL CHEMOTAXIS; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; BIOPSY; CHI SQUARE DISTRIBUTION; COLONOSCOPY; LONGITUDINAL STUDY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PREDICTION AND FORECASTING; REOPERATION; RISK FACTOR; STATISTICAL MODEL;

ADULT; BIOPSY; CHI-SQUARE DISTRIBUTION; COLECTOMY; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 77956629158     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181e751df     Document Type: Article

References (29)

1. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
2. Picco MF, Krishna M, Cangemi JR, et al. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. Inflamm Bowel Dis. 2006;12: 537-542.
3. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
4. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission ofsevere ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
5. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
6. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
7. Loftus EV Jr, Delgado DJ, Friedman HS, et al Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103:1737-1745.
8. Ardizzone S, Maconi G, Russo A, et al. Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
10. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455.
11. Tanaka M, Saito H, Kusumi T, et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring surgery. Scand J Gastroenterol. 2002;37:200-205.
12. Triantafillidis JK, Pomonis E, Emmanouilidis A, et al. Surgery for ulcerative colitis in Greece: clinicoepidemiological features and long-term outcome of 69 consecutive patients. Hepatogas-troenterology. 1998;45:961-968.
13. Hearing SD, Norman M, Probert CS, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45:382-388.
14. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-835.
15. Hefti MM, Chessin DB, Harpaz NH, et al. Severity ofinflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009;52:193-197.
16. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology. 1984;86:104-113.
17. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol. 1997;50:93-105.
18. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-409.
19. Schumacher G, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis: histologic course during the 1st year after presentation. Scand J Gastroenterol. 1994;29:318-332. (Pubitemid 24128379)
20. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105.
21. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-ami-nosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625-1629
22. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-211.
23. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178.
24. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. Br Med J. 1954;2:375-378.
25. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
26. Odze R, Antonioli D, Peppercorn M, et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol. 1993; 17:869-875.
27. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100:350-358.
28. Tanaka M, Riddell RH, Saito H, et al. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Scand J Gastroenterol. 1999;34: 55-67.
29. Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74-85. (Pubitemid 38375798)